Journal of Clinical Endocrinology & Metabolism, Vol 81, 3084-3090, Copyright © 1996 by Endocrine Society

ARTICLES

Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas

M Losa, M Giovanelli, L Persani, P Mortini, G Faglia and P Beck-Peccoz
Department of Neurosurgery, IRCCS San Raffaele, Ospedale Maggiore IRCCS, University of Milan, Italy.

The recorded number of patients with central hyperthyroidism due to TSH- secreting pituitary adenoma doubled in the last few years after the introduction of ultrasensitive TSH assays in the assessment of thyroid function; however, information about the results and the criteria for cure after pituitary surgery is scanty. Seventeen patients with a TSH- secreting adenoma, diagnosed on the basis of detectable TSH levels in the face of high free thyroid hormone concentrations and pituitary lesion at neuroimaging, underwent pituitary surgery. Hypersecretion of other pituitary hormones was diagnosed in 5 of 17 patients. Four patients were initially misdiagnosed and treated with thyroid surgery or radioiodine therapy. The majority (86%) of hyperthyroid patients normalized thyroid hormone concentrations and regained euthyroidism, although pituitary imaging, alpha-subunit, and alpha-subunit/TSH molar ratio normalized in only 47%, 54%, and 58% of patients, respectively. Moreover, TSH secretion was normally suppressed by T3 in 40% of the patients. Interestingly, the finding of undetectable TSH levels 7 days after surgery was highly predictive of successful outcome. During long term follow-up, there was one relapse of hyperthyroidism. Early diagnosis of TSH-secreting adenomas permits a high rate of remission of hyperthyroidism after surgery. However, normalization of thyroid function alone does not necessarily reflect complete removal of the tumor, and more comprehensive criteria of cure based on pituitary imaging, hormone measurement, and suppression of TSH during T3 administration should be used. Lastly, all patients need an accurate long term follow-up to monitor the possible recurrence of the adenoma.

This article has been cited by other articles:

				T. Kienitz, M. Quinkler, C. J Strasburger, and M. Ventz Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature Eur. J. Endocrinol., July 1, 2007; 157(1): 39 - 46. [Abstract] [Full Text] [PDF]

				S. A. Huang, S. A. Fish, D. M. Dorfman, D. Salvatore, H. P. W. Kozakewich, S. J. Mandel, and P. R. Larsen A 21-Year-Old Woman with Consumptive Hypothyroidism due to a Vascular Tumor Expressing Type 3 Iodothyronine Deiodinase J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4457 - 4461. [Abstract] [Full Text] [PDF]

				J. M. Kuhn, S. Arlot, H. Lefebvre, P. Caron, C. Cortet-Rudelli, F. Archambaud, P. Chanson, A. Tabarin, M. Goth, J. Blumberg, et al. Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1487 - 1491. [Abstract] [Full Text]

				M. Losa, R. L. A. Barzaghi, P. Mortini, A. Franzin, F. Mangili, M. R. Terreni, and M. Giovanelli Determination of the Proliferation and Apoptotic Index in Adrenocorticotropin-Secreting Pituitary Tumors : Comparison between Micro- and Macroadenomas Am. J. Pathol., January 1, 2000; 156(1): 245 - 251. [Abstract] [Full Text] [PDF]

				F. Brucker-Davis, E. H. Oldfield, M. C. Skarulis, J. L. Doppman, and B. D. Weintraub Thyrotropin-Secreting Pituitary Tumors: Diagnostic Criteria, Thyroid Hormone Sensitivity, and Treatment Outcome in 25 Patients Followed at the National Institutes of Health J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 476 - 486. [Abstract] [Full Text]